New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients
4 Articles
4 Articles
An experimental vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to a study published in the scientific journal Nature Medicine. The results are part of a randomized phase 2 clinical trial led by researchers from Mayo Clinic. Understand: man discovers plant growing in the eye after months of headache and double vision in Russia Why don't I recover from training as quickly as possib…
The results of a clinical trial showed that a new experimental vaccine for pancreatic cancer was able to stimulate an immune response in 98.9 per cent of patients whose response could be assessed, thereby enhancing hopes that genetic mutations associated with oncology could be developed and returned after treatment.
Phase 2 clinical trial tested immunizing in 144 people, but has not yet demonstrated that the strategy reduces the risk of disease return
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
